Background {#Sec1}
==========

Friedreich Ataxia (FRDA) is a neurological disease resulting in gait and balance abnormalities, sensory loss, weakness, loss of reflexes, and ataxia. A recessive disorder, FRDA can also result in scoliosis, urinary dysfunction, diabetes mellitus, optic atrophy, hearing loss, sleep apnea, and hypertrophic cardiomyopathy \[[@CR1]--[@CR8]\]. The disease is caused by expanded guanine-adenine-adenine (GAA) repeats on both alleles of the FXN gene (*FXN*) in 98 % of patients. The remaining 2 % of individuals with FRDA have an expanded triplet repeat on one allele and a point mutation or deletion on the other. FRDA is a mitochondrial disease, as the deficient protein in FRDA (frataxin) is crucial for mitochondrial iron-sulfur cluster containing enzymes involved in oxidative phosphorylation and the Krebs cycle \[[@CR9]--[@CR12]\]. There is currently no therapy for FRDA, though several clinical trials are ongoing \[[@CR13], [@CR14]\].

Although few manifestations outside of the typical features have been identified in FRDA, one previous report suggests an association of nephrotic syndrome (NS) with FRDA \[[@CR15]\]. In addition, related ataxias with coenzyme Q deficiency are associated with NS as are other mitochondrial disorders \[[@CR16], [@CR17]\]. Here we report 2 more individuals with NS and FRDA, providing further evidence for a possible connection between the two diseases and focusing on the responsiveness of one individual to corticosteroid treatment, an effect not previously described in FRDA.

Case Presentations {#Sec2}
------------------

Patient 1: The patient is a 13 year old female of European descent (GAA repeat lengths = 650, 1000). She presented with gait and balance difficulties at age 4 and was diagnosed with FRDA at age 5. At age 7, she developed periorbital edema, abdominal swelling, problems with urination, and a weight gain of 10 lbs over 9 months. She was diagnosed with idiopathic NS after laboratory testing revealing a urine protein of 2854 mg/dl and albumin of 2.2 g/dL. Though renal biopsy was not performed, specific causes of secondary nephrotic syndrome were ruled out by clinical criteria and serological testing. She received prednisone pulse therapy at 30 mg daily, which was tapered after 4 weeks. Her NS responded rapidly and urine protein levels normalized. She had 5 relapses of NS over the next 5 years, characterized by urine protein levels \>100 mg/dL, all treated with 30--60 mg daily of prednisone pulse therapy. Clinical manifestations and laboratory parameters (proteinuria) of NS resolved following steroid treatment; surprisingly, neurologic improvements were also noted by her caregiver and physical therapist. Specifically, after her first treatment with prednisolone, the patient's physical therapist noted that she had maintained range of motion in her heel cords and hamstrings and retained her skill level in balance as related to single leg stance over the course of a year. In the year following a second steroid treatment, the patient demonstrated decreased balance, coordination and range of motion. Subjectively her sense of fatigue decreased and her endurance improved. Objectively, her gait improved with a narrower base and fewer falls.

The effect was most prominent in a worsening of her neurologic abilities following scoliosis surgery. Following surgery she again developed NS and became unable to walk. Corticosteroid treatment led to recovery of renal function as well as ambulation. However, as her steroids were tapered, she lost ambulatory ability. This improved with another pulse of steroid treatment in the absence of NS.

Patient 2: The patient is a 25 year old male of Indian descent with FRDA (GAA repeats lengths = 650, 850). At age 2, the patient presented with periorbital edema, lethargy, and abdominal swelling. Idiopathic NS was confirmed following urine protein testing. He developed gait difficulties at age 9 and was diagnosed with FRDA at age 10. He had been treated with chronic steroids from age 2 to age 10, with doses ranging from 15 mg every other day to 60 mg per day during episodic flares. In response to the onset of gait problems, the patient's nephrologist switched him from steroid treatment to 100 mg of cyclophosphamide for 3 months. He has not had any relapses of NS since then. However, the patient's ataxia worsened after the discontinuation of steroids.

Given the improvement of the first subject on corticosteroid treatment, we examined the records of the Children's Hospital of Philadelphia (CHOP) and the Collaborative Clinical Research Network (CCRN) for other individuals reporting responses to corticosteroids prescribed for other indications in a retrospective review (Table [1](#Tab1){ref-type="table"}) \[[@CR18]\]. Nine people with FRDA experienced improved balance, gait or speech with corticosteroid or other immunomodulatory therapy, and no individuals were identified with significant steroid dependent worsening. One other patient treated with steroids showed improvement, although it is unclear whether improvement was due to corticosteroids or other medications initiated at the same time. All patients besides patients 1 and 2 described had normal kidney function.Table 1Patients with FRDA treated with steroidsPatient No. GAA repeatsAge of FRDA onsetClinical coursePhenotype^a^ImmunomodulatorDoseDurationReason for steroid treatmentResponseAge of steroid treatmentPatient 1 described\
650, 10004Began using wheelchair at age 10; scoliosis surgery at age 13Ataxia, loss of balance, loss of sensation, leg cramps, tremors, hypertrophic cardiomyopathy, scoliosis, fatiguePrednisolone, oral30 BID-50 QD26 months over 6 yearsNephrotic syndromeRecurrent neurologic improvement coincident with steroid dosing8--14Patient 2 described\
650, 95010Began using wheelchair at age 12Ataxia, loss of balance, loss of sensation, spasms, hypertrophic cardiomyopathy, arrhythmia, scoliosisPrednisone, oralunknown8 yearsNephrotic syndromePossible delay in presentation2--10Patient 3\
500, 57015Began using cane at 23, wheelchair at 29Ataxia, loss of balance, loss of sensation, leg spasms, restless legs, scoliosis, sleep apneaPrednisone and Medrol, oral8 QAM4--5 monthsChronic inflammatory demyelinating polyneuropathy (likely misdiagnosis)Mild improvements in gait, eventual progression18Patient 4\
725, presumed point mutation7Began using wheelchair at 17Ataxia, loss of balance, loss of sensation, leg spasms, restless legs, sleep apnea, fatigue, hypertrophic cardiomyopathy, scoliosisPrednisone, oral15--30 mg BID7 monthsChronic inflammatory demyelinating polyneuropathy (likely misdiagnosis)Improvements in balance, eventual progression12Patient 5\
unknownunknownUnknownUnknownPrednisoneunknownunknownRib fracturesImprovement in GaitunknownPatient 6\
1000, 10003Began using wheelchair at age 7Ataxia, loss of balance, loss of sensation, leg spasms, restless legs, increased tone, tremor, hypertrophic cardiomyopathy, scoliosisPrednisoloneunknownunknownChronic inflammatory demyelinating polyneuropathy (likely misdiagnosis)Improvement in gait and strength, eventual progression3Patient 7\
1113, point mutation2Began using walker at age 5Ataxia, loss of balance, loss of sensation, leg spasms, sleep apnea, hypertrophic cardiomyopathy, scoliosisMethylprednisolone, pulse therapy30 mg QD5 daysPneumonitisNo change in gait, balance, improved energy6Patient 8\
766, 10007Able to walk without assistive deviceMinimal ataxia, loss of balance, no scoliosis or cardiac screeningSolumedrol, oral5 mg TID5 monthsUnclearSustained improvements in balance, eventual progression9Patient 9\
41, 69643Began using a walker at age 58Ataxia, loss of balance, loss of sensation, leg spasms, increased toneDepomedrone, injection80 mg QD7--9 yearsSciatic painImprovements in gait and speech49Patient 10\
966, 10992Able to walk without assistive deviceAtaxia, loss of balance, loss of sensation, fatiguePrednisolone, oral30 mg OPD3 daysAcute laryngotra-cheitisImprovements in falling and fatigue8^a^Phenotype at closest exam to steroid use

There are several limitations to this study. Improvement in the context of corticosteroid treatment often occurred in the context of significant clinical changes, such as NS in the case of the two cases presented and surgery or trauma in other FRDA patients treated with steroids. Furthermore, in two cases, steroid treatment was initiated following intravenous immunoglobulin G treatment prescribed for chronic inflammatory demyelinating polyneuropathy and Guillain-Barre syndrome, both likely misdiagnoses for Friedreich Ataxia. This raises the possibility that in these cases concomitant intravenous immunoglobulin G treatment was at least partially responsible for noted improvements.

Conclusions {#Sec3}
===========

We describe two patients with FRDA and NS, one of whom demonstrated significant improvement with corticosteroid treatment. An association between FRDA and NS was initially reported in a single family in association with myoclonic epilepsy. Epilepsy was not identified in our subject, thus dissociating such findings (as predicted previously). As NS and FRDA are both rare, the present association in multiple unrelated subjects is unlikely to be coincidental. Furthermore, nephrotic syndrome has been documented in a variety of mitochondrial cytopathies and mutations in the synthesis of Coenzyme Q~10~ cause a subset of steroid-resistant nephrotic syndrome cases \[[@CR19], [@CR20]\]. Mitochondrial dysfunction is central to the pathophysiology of Friedreich Ataxia \[[@CR21]\]. Lack of frataxin disrupts the production of iron-sulfur clusters and increases levels of intracellular ROS in animal models,patient biopsies and FRDA fibroblasts, suggesting increased oxidative stress in FRDA cells \[[@CR10], [@CR22]--[@CR24]\]. Although the typical symptomatology of FRDA results from mitochondrial dysfunction in the spine, cerebellum and heart, we hypothesize that the cases of nephrotic syndrome in FRDA described result from mitochondrial involvement in renal cells.

Interestingly one of our subjects showed substantial neurological improvement following steroid treatment. No improvement in the non-neurological symptoms of FRDA were noted. Although this might represent a secondary event associated with improvement in her NS, we identified some degree of steroid responsiveness in her independent of NS and in other patients with FRDA. This could represent an anti-inflammatory effect (as two other patients responded transiently to intravenous immunoglobulin G) or could be the result of other effects of corticosteroids such as increased strength as a compensatory mechanism for balance dysfunction. The former possibility seems most likely, as a secondary inflammatory response in FRDA has been revealed in autopsy studies and in alterations of immune pathways in microarray analysis \[[@CR11], [@CR12]\]. This is felt to be the mechanism behind the well-documented response of Duchenne muscular dystrophy to corticosteroids \[[@CR25], [@CR26]\].

On the molecular level, it is possible that steroids modify the oxidative stress caused by frataxin deficiency and subsequent mitochondrial disease. This change in oxidative stress was hypothesized to be a cause for neurological improvement following steroid treatment in ataxia-telangiectasia \[[@CR27]\]. The catabolic effect of steroids could provide a mechanism for the improvements seen in FRDA, as altered lipid metabolism has been documented in rat myocytes with diminished frataxin levels and in *Drosophilia melanogaster* \[[@CR28], [@CR29]\]. The present patient, taken with previous basic and scientific research, suggests the importance of pilot studies examining the efficacy of pulse steroid treatment as a potential therapy in FRDA.
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